SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
This is a clear disclosure of shareholder vote results from Colony Bankcorp's Annual Meeting held on May 21, 2026, covering three proposals: election of eight directors, advisory say-on-pay vote, and ratification of auditors. The filing presents detailed voting tallies (votes for, against, withheld, abstentions, and broker non-votes) for each matter, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Babcock & Wilcox held its Annual Meeting of Stockholders on May 20, 2026, with voting results on seven proposals including director elections, charter amendments, auditor ratification, executive compensation approval, and a plan amendment. Two charter amendment proposals (Proposals 1 and 4) failed to achieve the required 80% approval threshold.
View raw filing on EDGAR →Stockholders approved an amendment to the 2021 Long-Term Incentive Plan that increased the authorized share pool for award grants from 5.25 million to 10.25 million shares, materially expanding the equity available for executive and employee compensation.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of Alpine Income Property Trust's 2026 Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes for three proposals: election of five directors, a non-binding say-on-pay vote, and ratification of Grant Thornton LLP as independent auditor. The filing presents detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →Travelers Companies held its annual meeting of shareholders on May 20, 2026, and disclosed the voting results for six items: election of eight directors, ratification of the independent auditor, non-binding executive compensation vote, amendment to the 2023 Stock Incentive Plan increasing authorized shares by 5,000,000, and two shareholder proposals.
View raw filing on EDGAR →TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market, with reported stockholders' equity of only $1,251,427 as of March 31, 2026. The company has 45 days to submit a compliance plan, and failure to regain compliance could result in delisting. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses a Settlement, Release and Amendment Agreement between Navitas and Live Oak Sponsor Partners II regarding earnout shares from the 2021 business combination. The settlement involves transfer of 726,225 previously unvested earnout shares to Live Oak Sponsor, forfeiture of 115,775 shares, and mutual releases of claims. While this involves earnout mechanics from a prior M&A transaction, the core event is a settlement agreement resolving disputes—not the M&A activity itself (which occurred in 2021). This settlement is material as it resolves contingent equity obligations and disputes, but does not fit cleanly into ma_activity (no new acquisition/disposition), exec_compensation (not executive compensation), or dilutive_issuance (shares already contemplated in the 2021 deal). The event is best classified as other_material given its settlement nature and material impact on earnout obligations.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Solstice Advanced Materials' Annual Meeting of Shareowners held on May 22, 2026, including voting outcomes on four matters: election of four Class I directors (Peter Gibbons, Rose Lee, William Oplinger, Patrick Ward), appointment of Deloitte & Touche LLP as independent auditors, advisory approval of named executive officer compensation, and frequency of future advisory votes on compensation. The filing directly matches the shareholder_vote_results event type and is material as it documents formal governance actions and shareholder approval of key corporate matters.
View raw filing on EDGAR →Westwater Resources held its Annual Stockholder Meeting on May 22, 2026, at which shareholders voted on and approved six proposals: director elections, an incentive plan amendment, an increase in authorized common shares from 200 million to 400 million, an advisory vote on executive compensation, auditor ratification, and approval of a convertible note issuance.
View raw filing on EDGAR →The Company issued 3,277,438 shares of Class A common stock on May 22, 2026, in satisfaction of contingent consideration obligations under the Business Combination Agreement. This represents a dilutive issuance tied to a prior M&A transaction (the 2021 business combination with Legacy Navitas), with additional contingent shares (up to 10,000,000 total) potentially issuable if stock price targets are met before October 2026. The disclosure of actual share issuance and the magnitude of contingent consideration makes this material to investors assessing ownership dilution and future capital structure.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of the 2026 annual meeting of unitholders held on May 20, 2026, where unitholders voted on three matters: election of four Class I directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of 2025 named executive officer compensation. The filing provides detailed voting tallies and percentages for each matter, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of United Airlines' Annual Meeting held on May 19, 2026. The filing presents voting results for four matters: election of 11 directors (all elected), ratification of Ernst & Young LLP as independent auditor, advisory approval of executive compensation, and a shareholder proposal on written consent rights (rejected). These are routine but material governance events that affect investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of PAGP's 2026 annual meeting of shareholders held on May 20, 2026, including voting outcomes on three matters: election of four Class I directors (all passing with 97.8%–98.4% support), ratification of PricewaterhouseCoopers LLP as independent auditor (98.7% support), and advisory approval of 2025 named executive officer compensation (64.4% support). The disclosure of shareholder vote results at an annual meeting is a core Item 5.07 event and is material to investors as it reflects governance decisions and shareholder sentiment.
View raw filing on EDGAR →BKV entered into a Sixth Amendment to its reserve-based lending agreement on May 20, 2026, which relaxes key financial covenants by increasing maximum permitted net leverage ratios across restricted payments, debt prepayments, and permitted investments. While this is a material credit agreement amendment affecting the company's financial flexibility and covenant compliance, it does not fit cleanly into the more specific event categories (not an M&A activity, covenant breach, or dilutive issuance). The amendment signals potential financial stress or tightening liquidity, but the disclosure itself is of a covenant waiver/amendment rather than a breach or going-concern issue.
View raw filing on EDGAR →Hyatt Hotels held its Annual Meeting of Stockholders on May 20, 2026, with voting results on director elections (Class II directors Gianni Marostica, Heidi O'Neill, and Richard C. Tuttle), ratification of Deloitte & Touche LLP as independent auditor, a stockholder proposal on plastics disclosure (not approved), and advisory approval of named executive officer compensation.
View raw filing on EDGAR →Paul D. Ballew retired from the Board on May 20, 2026, and Thomas J. Pritzker did not stand for re-election at the May 20, 2026 Annual Meeting, reducing the Board from twelve to ten members.
View raw filing on EDGAR →PepsiCo terminated and replaced two material credit facilities totaling $10 billion ($5B 364-day and $5B five-year revolving credit agreements). While routine credit facility renewals are common, the disclosure of these $5 billion facilities and their replacement terms is material to investors assessing the company's liquidity and financing capacity. This does not fit neatly into the more specific event categories (not a covenant breach, not a going-concern issue, not M&A activity), making "other_material" the most appropriate classification.
View raw filing on EDGAR →FedEx announced the full redemption of €354.9 million in 1.300% Notes due 2031, with a redemption price of €358.6 million (including accrued interest) payable on May 28, 2026. This is a material debt management event affecting the company's capital structure and liquidity, but does not fit neatly into the more specific event categories (it is neither a covenant breach, dilutive issuance, nor M&A activity). The redemption represents a significant financial obligation and refinancing decision material to investors.
View raw filing on EDGAR →AvalonBay Communities held its Annual Meeting on May 20, 2026, with stockholders voting on four proposals: election of 12 directors, advisory approval of executive compensation, approval of the 2026 Equity Incentive Plan, and ratification of Ernst & Young LLP as independent auditors. The filing reports detailed vote tallies for each proposal.
View raw filing on EDGAR →Molson Coors disclosed the entry into underwriting and purchase agreements for $1.5 billion in aggregate principal amount of senior notes ($500M USD 4.900% due 2031, $1.0B USD 5.500% due 2036, and C$500M CAD 4.300% due 2033). While debt issuance is material to investors, it does not fit neatly into the specific event categories (not M&A, not a restatement, not a covenant breach, etc.). This is a material financing event that would affect investor assessment of the company's capital structure and liquidity, warranting classification as other_material.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from SmartFinancial's 2026 annual meeting held on May 21, 2026. The filing reports voting outcomes for three proposals: election of ten directors, ratification of Elliott Davis, PLLC as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and management accountability.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Community Financial System's Annual Shareholders Meeting held on May 20, 2026, including the election of 12 directors, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents detailed voting tallies for each director and each proposal, which is the core content of shareholder vote results disclosures.
View raw filing on EDGAR →Solana Co held its annual meeting of security holders on May 21, 2026, with shareholders voting on three proposals: election of four directors (Proposal 1), ratification of CBIZ CPAs P.C. as independent auditor (Proposal 2), and election of two additional directors (Proposal 3). Detailed vote tallies for each nominee and proposal are disclosed.
View raw filing on EDGAR →Effective at the Annual Meeting, the audit committee was reconstituted with Blane Walter as Chair and Edward M. Straw and Michel Lee as members. This governance change affects the registrant's control environment and audit oversight.
View raw filing on EDGAR →McEwen Inc. received a $49.4 million dividend from its 46.3% ownership stake in McEwen Copper Inc., bringing 2026 total dividends to $58.2 million from the San José mine operations. While this represents a significant cash inflow and is material to investors assessing the company's financial position and cash generation, it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or other defined event types). The disclosure is material because it affects the total mix of information about the registrant's financial performance and liquidity.
View raw filing on EDGAR →Curis held its Annual Meeting of Stockholders on May 22, 2026, with voting results on five proposals: election of Class III directors (Greenacre and Kaitin), advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, amendment to increase authorized common shares from 283.8M to 567.5M, and adjournment proposal.
View raw filing on EDGAR →Stockholders approved material amendments to the Certificate of Incorporation: doubling authorized common shares from 283.8M to 567.5M and eliminating Series A and Series B Preferred Stock designations, representing a significant capital structure change.
View raw filing on EDGAR →Integer Holdings amended employment and change-of-control agreements for five named executives, including CEO Payman Khales, to accelerate vesting of performance-based equity upon termination in connection with a change of control, and approved cash retention bonuses totaling approximately $4.4 million across the five executives.
View raw filing on EDGAR →Integer Holdings held its Annual Meeting of Stockholders at which stockholders approved all four proposals: election of 11 directors, ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and approval of the 2026 Omnibus Incentive Plan.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Hope Bancorp's 2026 annual meeting held on May 21, 2026. The filing reports voting outcomes on three proposals: election of nine directors, ratification of Crowe LLP as independent auditor, and an advisory vote on named executive officer compensation. The detailed vote tallies and approval percentages are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →The disclosure announces presentation of translational data from clinical studies (GOBLET and AWARE-1) at a major medical conference (ASCO Annual Meeting), describing pelareorep's mechanism of action and immune system effects. While this represents material clinical/scientific progress for a biotech company, it does not fit neatly into more specific event categories (not an earnings release, not a regulatory approval, not a material impairment or litigation). The announcement of clinical data presentation at a major conference would be material to investors assessing the company's pipeline and therapeutic potential.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Momentus Inc.'s 2026 Annual Meeting of Stockholders held on May 19, 2026, covering six proposals: election of two directors (Chris Hadfield and John C. Rood), ratification of auditors (Frank, Rimerman + Co. LLP), approval of equity incentive plan amendments, evergreen share increases, say-on-pay advisory vote, and say-on-pay frequency. All proposals passed. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance actions and executive compensation arrangements.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of the Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes for three proposals: election of nine directors, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →Hilton Grand Vacations entered into Omnibus Amendment No. 5 to its material receivables loan agreement, increasing the facility size from $850 million to $1 billion, extending the revolving period to May 2028, and expanding collateral eligibility to include Elara timeshare loans. This material amendment to a significant credit facility affects the company's liquidity and capital structure.
View raw filing on EDGAR →DevvStream Corp. disclosed multiple delisting risks under Item 3.01: failure to comply with Nasdaq Listing Rule 5550(b) (Net Income Requirement of $500,000 minimum) and Nasdaq Listing Rule 5450(a)(1) (Minimum Bid Price Rule of $1.00 per share). The company received formal notification on May 20, 2026 that it has not regained compliance with the Net Income Requirement, and a Nasdaq Hearings Panel will consider both deficiencies in deciding whether to suspend/delist the company's common shares. The filing explicitly states "there can be no assurance that the Company will be able to regain compliance or maintain its listing on Nasdaq," indicating imminent delisting risk.
View raw filing on EDGAR →Atlantic American Corporation received a formal notice from Nasdaq on May 21, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q and Form 10-K. The company has until June 16, 2026 to submit a compliance plan, with potential delisting consequences if the plan is not accepted. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →Anteris Technologies entered into a Sales Agreement with TD Cowen authorizing an "at the market" offering of up to $250 million in common stock. This is a dilutive equity issuance that would materially affect existing shareholders through potential dilution. The filing explicitly describes the offering structure, commission terms, and use of proceeds for product development, which are hallmarks of a material capital raise disclosed under Item 1.01.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final results of Beta Bionics' 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing presents detailed voting tallies for two proposals: election of directors (Sean D. Carney and Christy Jones as Class I directors) and ratification of Ernst & Young LLP as the independent auditor. Both proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm governance and audit oversight decisions.
View raw filing on EDGAR →Corpay entered into the Eighteenth Amendment to its Credit Facility on May 21, 2026, materially restructuring its debt by increasing revolving commitments by $0.9 billion to $3.7 billion, increasing Term Loan A by $0.4 billion to $3.3 billion, increasing Term Loan B-6 by $2.05 billion to $2.95 billion, and extending maturities by 5 years.
View raw filing on EDGAR →Shareholders approved a reverse stock split (1-for-5 to 1-for-10 ratio) and amendment to the certificate of incorporation at a special meeting held on May 19, 2026, with 44,826,378 votes in favor, 6,708,960 against, and 102,965 abstained.
View raw filing on EDGAR →The Board approved and the company announced a 1-for-8 reverse stock split of SCYNEXIS common stock, effective May 29, 2026, which was previously authorized by stockholders and affects share structure, authorized shares, and trading mechanics.
View raw filing on EDGAR →REalloys Inc. entered into a 15-year Rare Earth Product Offtake Agreement with Critical Metals Corp on May 18, 2026, committing to purchase 15% of Phase 1 production from the Tanbreez rare earth element mining project in Greenland. This is a material definitive agreement disclosed under Item 1.01 that establishes a long-term supply commitment with pricing mechanisms tied to market indices and floor prices, representing a significant commercial arrangement that would affect investor assessment of the company's strategic positioning and revenue streams.
View raw filing on EDGAR →The filing discloses interim clinical trial results being presented at a major oncology conference (ASCO 2026). While this could represent material clinical progress for a therapeutics company, the Item 8.01 disclosure lacks sufficient detail to confirm whether these results constitute a formal earnings release, material impairment, or other specific event type. The announcement of interim trial data at a scientific conference is material to investors but does not fit cleanly into the more specific taxonomy categories.
View raw filing on EDGAR →Dominion Energy disclosed entry into an Agreement and Plan of Merger with NextEra Energy on May 15, 2026, whereby NextEra's subsidiary will merge with Dominion Energy, with Dominion surviving as a wholly owned subsidiary of NextEra. This is a material acquisition/change of control transaction subject to shareholder and regulatory approvals, including HSR clearance and approvals from FERC, NRC, and state utility commissions. The filing extensively discusses closing conditions, risks, and restrictions on Dominion's business pending completion—all hallmarks of a material M&A event.
View raw filing on EDGAR →XOMA Royalty Corp held its 2026 Annual Meeting of Stockholders on May 21, 2026, where stockholders approved five proposals: election of seven directors, ratification of Deloitte & Touche LLP as independent auditor, amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan (increasing available shares by 425,000 and extending the term to 2036), approval of the 2026 Employee Stock Purchase Plan (500,000 shares available), and advisory approval of named executive officer compensation. All proposals passed with substantial majorities.
View raw filing on EDGAR →The company adopted bylaw amendments in connection with a pending merger with Ligand Pharmaceuticals, including provisions related to Nevada controlling interest statutes and exclusive forum selection that affect shareholder rights and dispute resolution procedures.
View raw filing on EDGAR →Assembly Biosciences announced a material expansion of its lead clinical candidate ABI-6250 from HDV infection into two additional cholestatic liver disease indications (PBC and PSC), with Phase 2 trials planned for Q4 2026 and Q1 2027, supported by preclinical data and constructive FDA pre-IND meeting feedback.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the May 20, 2026 Annual Meeting of Stockholders, including election of two Class III directors (Alan B. Miller and Nina Chen-Langenmayr), advisory approval of named executive compensation, ratification of PricewaterhouseCoopers as independent auditor, and rejection of a stockholder proposal on shareholder money at risk reporting. The filing provides detailed vote tallies for each proposal, which is the core content of Item 5.07.
View raw filing on EDGAR →The disclosure centers on a compensatory arrangement modification for Francis X. Brown III, the Interim Principal Financial and Accounting Officer. The Company amended his consulting agreement on May 18, 2026 to change compensation from a fixed hourly rate to $26,000 per month, which is a material modification to executive compensation terms. While Brown's appointment as Interim PAO was previously announced, this Item 5.02(e) filing focuses on the amended compensation structure, making exec_compensation the most salient classification.
View raw filing on EDGAR →William K. 'Dan' Daniel was elected as Independent Chairman of the Board of Directors at the Annual Meeting, a material appointment to a senior governance role.
View raw filing on EDGAR →